PROductivity Study of Presbyopia Elimination in Rural-dwellers II (PROSPERII)

November 30, 2023 updated by: Nathan Congdon, Queen's University, Belfast

Effects of Near Vision Spectacle Correction on Work Productivity Among Textile Factory Workers in India

The investigators will conduct a randomized-controlled trial. The participants will be textile workers aged 30 years and above with uncorrected presbyopia who are employed by a single Indian garment manufacturer - employed by Shahi Exports Private Limited, Karnataka, India - at facilities equipped to measure individual productivity. PROSPER II will assess the impact of free reading glasses on productivity for workers in a textile factory.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Globally, 3 billion people do not have the eyeglasses they need to earn, learn, travel safely in traffic and participate in civic life. Among these, 1.1 billion people lack a simple pair of reading glasses to correct impaired near vision, called presbyopia. Presbyopia, the essentially universal decline in unaided near vision that occurs with aging, is the world's most common cause of vision impairment. Loss of accommodation (ability to change focus from distance to near) due to presbyopia can begin as early as age 30 years, commonly becomes functionally apparent by 40, and is essentially complete by 55, meaning that presbyopia is most common at the height of the working years.

Study Plan: This is a randomized trial designed to assess the impact of free spectacles on workplace productivity among Indian textile workers.

Research question: Will providing free glasses to presbyopic Indian textile workers increase work productivity?

Design: Investigator-masked, multi-center randomized controlled trial

Rationale: Although presbyopia is safely, effectively and inexpensively treated with glasses, rates of optical correction in LMICs are as low as 10%. The global productivity loss due to uncorrected presbyopia has been estimated to exceed US$25 billion, and presbyopia is shown to be associated with significant impairment in activities of daily living. Few trials have been published which address the question of whether healthcare interventions can improve work performance as well as workplace retention, especially among persons over the age of 40 in low and middle-income countries (LMICs). The largest reported effect sizes among such trials was the PROSPER trial, which showed that providing inexpensive near vision glasses increased the daily weight of tea picked among presbyopic, mostly-female Indian agricultural workers by more than 5 kg (21.6%) compared to those in the control group. Costs were low, over half of pickers aged >= 40 years met criteria to receive glasses, and wearing compliance reached nearly 90%. There is interest to understand if these results from the agricultural setting can be extended to other financially-important sectors.

Methods : The investigators will enrol 800 textile workers aged 35 years and above with uncorrected presbyopia who are employed by Shahi Exports Private Limited in Karnataka, India. Eligible participants will be randomly assigned to Intervention and Control Groups (1:1). Intervention group participants will receive free reading glasses within a week of undergoing a vision screening at the factory. Control group participants will receive reading glasses at the end of the assessment period (three months after vision screening).

The main outcome 3 month later will be work productivity; secondary outcomes are change in skill grade, change in monthly wage, participants' adherence with spectacle wear, self-assessed self-efficacy score and change of quality of life scores. The intervention cost-effectiveness will be studied.

Study Type

Interventional

Enrollment (Estimated)

800

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Aged 35 years and older
  • Have presbyopia, defined as an unaided near visual acuity of N6.3 or worse in both eyes
  • Require a new pair of glasses to improve their near vision
  • Have a corrected near visual acuity of N4 or better in both eyes
  • Have worked in Shahi's production department as tailors or Kajbutton operators for 6 weeks or more

Exclusion Criteria:

  • Have ocular pathology in either eye detected during the eye examination, or history of such disease based on self-report
  • Have a low likelihood of completing follow-up in the study due to current plans to move out of the area or leave employment at Shahi during the follow-up period

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
Workers assigned to the intervention group will receive free spectacles of a design they select, based on the worker's measured refractive power and dispensed one week later at the factory by the study ophthalmic personnel.
Intervention group workers receive free glasses within one week of undergoing vision assessment (September 2021). The assessment period will be three months
Other Names:
  • Near eyeglasses
  • Reading glasses
No Intervention: Control
Workers assigned to the Control group will receive similar free glasses at the end of the study assessment (3 months).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in change in mean efficiency between intervention and control group
Time Frame: Over the three month follow-up period from enrolment to study completion
Efficiency is calculated as the proportion of target production realized by a worker per unit time
Over the three month follow-up period from enrolment to study completion

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Three-month change in skill grade
Time Frame: Between baseline and study end three months later
Skill grade ranges from A triple star (highest) to A double star, A star, A, B, and C + (lowest)
Between baseline and study end three months later
Change in monthly wage
Time Frame: Between baseline and study end three months later
Monthly wage (Factory administrative data)
Between baseline and study end three months later
Adherence with spectacle wear
Time Frame: Between baseline and study end three months later
measured weekly by enumerator's unannounced observations of the presence of spectacles worn on the participant's face.
Between baseline and study end three months later
Group difference in three-month change in self-assessed self-efficacy scores
Time Frame: Between baseline and conclusion of the study three months later
Self-assessed self-efficacy scores measured using the Cantril's Ladder, with the best possible score being a 10, and the worst being a 0 (Cantril's Ladder)
Between baseline and conclusion of the study three months later
Group difference in three-month change of quality of life scores
Time Frame: Between baseline and conclusion of the study three months later
Quality of life scores measured using the APEDS Visual Function Questionnaire (VFQ)
Between baseline and conclusion of the study three months later
Cost effectiveness
Time Frame: Between baseline and study end three months later
Full programme costs per individual identified and corrected with presbyopia. Programme costs include costs incurred in screening test, glasses / replacement and direct/indirect costs for facilitating work-based site. Benefit will be measured using work productivity. We will report cost effectiveness distinguishing between study costs and program costs
Between baseline and study end three months later

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Nathan G Congdon, MD, MPH, Queen's University, Belfast

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 3, 2023

Primary Completion (Estimated)

June 30, 2024

Study Completion (Estimated)

June 30, 2024

Study Registration Dates

First Submitted

October 21, 2020

First Submitted That Met QC Criteria

November 10, 2020

First Posted (Actual)

November 16, 2020

Study Record Updates

Last Update Posted (Estimated)

December 7, 2023

Last Update Submitted That Met QC Criteria

November 30, 2023

Last Verified

November 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MHLS 20_82

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified data will be made available for download on the Queen's University Belfast website.

IPD Sharing Time Frame

Within 6 months of collection, for three years.

IPD Sharing Access Criteria

Freely available

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ANALYTIC_CODE
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Presbyopia

Clinical Trials on Spectacles

3
Subscribe